<DOC>
	<DOC>NCT00224107</DOC>
	<brief_summary>A new drug for benign prostatic hyperplasia is compared to placebo for to determine if it is safe and effective. The study lasts approximately 20 weeks.</brief_summary>
	<brief_title>A New Drug for Benign Prostatic Hyperplasia (BPH) Compared With Placebo</brief_title>
	<detailed_description>This will be a multi-center, double-blind, placebo controlled, parallel, 12 week treatment trial in men with signs and symptoms of benign prostatic hyperplasia. The following procedures are utilized: physical exams, electrocardiograms, clinical laboratory tests, vital signs, the International Prostate Symptom Score, maximum urine flow rate, pharmacokinetics, adverse events, concomitant medications, quality of life, and compliance.</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Silodosin</mesh_term>
	<criteria>Males in good general health and at least 50 years of age, with symptoms of moderate to severe benign prostatic hyperplasia. Medical conditions that would confound the efficacy evaluation. Medical conditions in which it would be unsafe to use an alphablocker. The use of concomitant drugs that would confound the efficacy evaluation. The use of concomitant drugs that would be unsafe with this alphablocker.</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Benign prostatic hyperplasia, BPH, alpha blocker</keyword>
</DOC>